The State of State Biomarker Testing Insurance Coverage Laws-Reference-Cited by-同舟云学术

The State of State Biomarker Testing Insurance Coverage Laws

Published:2024-06-11 Issue:22 Volume:331 Page:1885
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Lin Grace A.¹²,Coffman Janet M.²,Phillips Kathryn A.¹²

Affiliation:

1. Center for Translational and Policy Research on Precision Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco

2. Institute for Health Policy Studies, University of California, San Francisco

Abstract

This Viewpoint discusses laws mandating insurance coverage of biomarker testing to broaden access to care for patients with cancer.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jama/articlepdf/2818623/jama_lin_2024_vp_240039_1717088630.32702.pdf

Reference7 articles.

1. The effects of federal parity on mental health services use and spending: evidence from the Medical Expenditure Panel Survey.;Drake;Psychiatr Serv,2019

2. Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States.;Bruno;JCO Precis Oncol,2022

3. State legislative trends related to biomarker testing.;Sadigh;Cancer,2022

4. Practice-level variation in molecular testing and use of targeted therapy for patients with non–small cell lung cancer and colorectal cancer.;Roberts;JAMA Netw Open,2023

5. Mandated coverage for cancer-screening services: whose guidelines do states follow?;Rathore;Am J Prev Med,2000

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State Biomarker Testing Insurance Coverage Laws;JAMA;2024-09-12

2. State Biomarker Testing Insurance Coverage Laws—Reply;JAMA;2024-09-12

3. Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned;Clinical Pharmacology & Therapeutics;2024-08-21

4. Circulating Tumor DNA for Solid Tumor Minimal/Molecular Residual Disease Detection in Cancer Survivors;The American Journal of Medicine;2024-08